人类疾病中Toll样受体导向疗法的最新进展。
Update on toll-like receptor-directed therapies for human disease.
作者信息
Tse Kevin, Horner Anthony A
机构信息
Department of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail code 0663, La Jolla, CA 92093-0663, USA.
出版信息
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii77-80. doi: 10.1136/ard.2007.078998.
Abstract
Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand-based therapies for the treatment of diseases in humans.
摘要
对微生物的固有反应在很大程度上由Toll样受体（TLR）介导，这些受体可识别病毒、细菌和真菌产生的多种分子。人们付出了巨大努力，致力于将这一知识转化为针对多种疾病（包括感染性疾病、恶性肿瘤、自身免疫性疾病和过敏性疾病）开发新疗法。本综述将简要介绍基于TLR配体疗法治疗人类疾病的已完成、正在进行和计划中的临床试验的最新情况。
相似文献
1
Update on toll-like receptor-directed therapies for human disease.
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii77-80. doi: 10.1136/ard.2007.078998.
2
The future of toll-like receptor therapeutics.
Curr Opin Mol Ther. 2008 Feb;10(1):21-31.
3
Update on toll-like receptor ligands and allergy: implications for immunotherapy.
Curr Allergy Asthma Rep. 2006 Sep;6(5):395-401. doi: 10.1007/s11882-996-0012-9.
4
Immunology. Targeting the tolls.
Science. 2006 Apr 14;312(5771):184-7. doi: 10.1126/science.312.5771.184.
5
[Responses with participation of toll-like receptors in protective immunity and in pathologic states].
Ukr Biokhim Zh (1999). 2008 May-Jun;80(3):5-20.
6
The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
Immunopharmacol Immunotoxicol. 2009;31(3):331-8. doi: 10.1080/08923970902802926.
7
Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
Front Immunol. 2020 Nov 12;11:599083. doi: 10.3389/fimmu.2020.599083. eCollection 2020.
8
Prophylactic and therapeutic implications of toll-like receptor ligands.
Med Res Rev. 2012 Mar;32(2):294-325. doi: 10.1002/med.20214. Epub 2010 Oct 25.
9
Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.
Drug Discov Today. 2007 Jan;12(1-2):80-7. doi: 10.1016/j.drudis.2006.11.007. Epub 2006 Nov 28.
10
Immunostimulatory oligonucleotides in therapy of allergic diseases.
Expert Opin Biol Ther. 2005 Apr;5(4):525-36. doi: 10.1517/14712598.5.4.525.
引用本文的文献
1
Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Front Immunol. 2023 Oct 23;14:1227833. doi: 10.3389/fimmu.2023.1227833. eCollection 2023.
2
E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2.
Cell Death Differ. 2023 Apr;30(4):966-978. doi: 10.1038/s41418-023-01115-2. Epub 2023 Jan 21.
3
NF-kB as a key player in regulation of cellular radiation responses and identification of radiation countermeasures.
Discoveries (Craiova). 2015 Mar 31;3(1):e35. doi: 10.15190/d.2015.27.
4
Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases.
Adv Pharm Bull. 2015 Dec;5(Suppl 1):605-14. doi: 10.15171/apb.2015.082. Epub 2015 Dec 31.
5
Metal-Based Nanoparticles and the Immune System: Activation, Inflammation, and Potential Applications.
Biomed Res Int. 2015;2015:143720. doi: 10.1155/2015/143720. Epub 2015 Jun 1.
6
Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus.
Indian J Hum Genet. 2012 May;18(2):155-60. doi: 10.4103/0971-6866.100750.
7
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
Expert Rev Clin Pharmacol. 2011 Mar;4(2):275-89. doi: 10.1586/ecp.11.5.
8
The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.
J Clin Aesthet Dermatol. 2010 Sep;3(9):20-9.
9
Helminth cysteine proteases inhibit TRIF-dependent activation of macrophages via degradation of TLR3.
J Biol Chem. 2010 Jan 29;285(5):3383-92. doi: 10.1074/jbc.M109.060368. Epub 2009 Nov 18.
10
Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA.
Nature. 2008 Jul 24;454(7203):523-7. doi: 10.1038/nature07106. Epub 2008 Jun 11.
本文引用的文献
1
The treatment of viral infections and nonmelanoma skin cancers.
Cutis. 2007 Apr;79(4 Suppl):29-35.
2
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.
Nat Med. 2007 May;13(5):552-9. doi: 10.1038/nm1589.
3
Development of TLR9 agonists for cancer therapy.
J Clin Invest. 2007 May;117(5):1184-94. doi: 10.1172/JCI31414.
4
The antitumoral mode of action of imiquimod and other imidazoquinolines.
Curr Med Chem. 2007;14(6):681-7. doi: 10.2174/092986707780059625.
5
Regulatory T cells and cancer.
Curr Opin Immunol. 2007 Apr;19(2):217-23. doi: 10.1016/j.coi.2007.02.004. Epub 2007 Feb 15.
6
Cellular and molecular mechanisms of tumor-induced T-cell tolerance.
Curr Cancer Drug Targets. 2007 Feb;7(1):41-53. doi: 10.2174/156800907780006940.
7
Indoleamine 2,3-dioxygenase in immune suppression and cancer.
Curr Cancer Drug Targets. 2007 Feb;7(1):31-40. doi: 10.2174/156800907780006896.
8
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
Expert Rev Vaccines. 2006 Oct;5(5):617-29. doi: 10.1586/14760584.5.5.617.
9
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
Leukemia. 2007 Jan;21(1):53-60. doi: 10.1038/sj.leu.2404456. Epub 2006 Oct 26.
10
Dendritic cells: translating innate to adaptive immunity.
Curr Top Microbiol Immunol. 2006;311:17-58. doi: 10.1007/3-540-32636-7_2.
Zotero 插件